KINACEPT
Novel anti-inflammatory compounds for autoimmune diseases
| Coordinatore | SYNOVO GMBH
Organization address
address: Paul Ehrlich Str 15 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.medizin3.uk-erlangen.de/e1846/e623/e719/index_ger.html |
| Totale costo | 1˙475˙995 € |
| EC contributo | 1˙041˙700 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2007-1 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-12-01 - 2010-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SYNOVO GMBH
Organization address
address: Paul Ehrlich Str 15 contact info |
DE (TUEBINGEN) | coordinator | 0.00 |
| 2 |
CAIR BIOSCIENCES GMBH
Organization address
address: PAUL EHRLICHSTRASSE 15 contact info |
DE (TUBINGEN) | participant | 0.00 |
| 3 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 0.00 |
| 4 |
EPISTEM LTD
Organization address
address: GRAFTON STREET INCUBATOR BLDG 48 contact info |
UK (MANCHESTER) | participant | 0.00 |
| 5 |
FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG
Organization address
address: SCHLOSSPLATZ 4 contact info |
DE (ERLANGEN) | participant | 0.00 |
| 6 |
INTE:LIGAND SOFTWARE-ENTWICKLUNGS- UND CONSULTING GMBH
Organization address
address: Clemens-Maria Hofbauer Gasse 6 contact info |
AT (MARIA ENZERSDORF) | participant | 0.00 |
| 7 |
QUEEN MARY UNIVERSITY OF LONDON
Organization address
address: 327 MILE END ROAD contact info |
UK (LONDON) | participant | 0.00 |
| 8 |
ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH
Organization address
address: AUERBACHSTRASSE 112 contact info |
DE (STUTTGART) | participant | 0.00 |
| 9 |
UNIVERSITA DEGLI STUDI DI PERUGIA
Organization address
address: PIAZZA DELL' UNIVERSITA 1 contact info |
IT (PERUGIA) | participant | 0.00 |
| 10 |
USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE
Organization address
address: VIDENSKA 1083 contact info |
CZ (PRAHA 4) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition, feedback from licensing partners has indicated that clear activity in a range of other disease models would dramatically increase interest. A key issue in bringing substances of this class to the clinic is variable patient response to p38 inhibitors in previous trials. Data to date have indicated that there is a potential groups of responders for whom therapy with this class is highly beneficial. The effect of non-responders has, however, made trial outcomes to variable to warrant further development. To solve this problem, we intend to further extend proof-of-concept in patient stratification to allow us to select responder populations for initial patient trials. The objectives of the project are, therefore: § To prepare analogs of the existing compounds § Conduct pre-clinical models for rheumatoid arthritis, IBD, sepsis, liver fibrosis and motilin dependent gut stimulation § Examine the activity of the compounds in human tissue explant models § Select a pre-clinical candidate class § Develop a scaled-up process for GMP synthesis of the lead § Conduct a survey of p38 expression in IBD and RA sub-types at various stages of disease and correlate this plasma markers. § Based on results of tissue explant studies and p38 expression, select a patient stratification protocol for phase 2A studies in man.'